Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections. They’re both prescribed for asthma and chronic rhinosinusitis with nasal polyps. Each drug may also be ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant decrease in the annualised rate of moderate/severe e ...

Nucala (mepolizumab) is a prescription injection used to treat a type of asthma and other inflammatory conditions. Nucala isn’t known to interact with other drugs, alcohol, or supplements.

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

2025 Healthcare & Pharmaceuticalscategory European regulators to review GSK's asthma drug Nucala to treat COPD March 24, 2025 Healthcare & Pharmaceuticalscategory Brazil's Hypera to launch an ...

American Depositary Receipts (ADR) are US-listed securities that represent shares in foreign companies, allowing American ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...